CFTR corrector 2 is a small-molecule chemical reagent primarily used in research for cystic fibrosis, a genetic disorder affecting the lungs and digestive system. It targets the underlying cause of the disease by correcting the folding and trafficking defects of the malfunctioning CFTR protein, enabling it to reach the cell surface and function properly. In cellular and animal models, it improves CFTR activity, reducing the accumulation of thick, sticky mucus in the lungs—a key feature of cystic fibrosis. This leads to enhanced lung function, fewer respiratory infections, and better overall outcomes in research settings. It is often studied in combination with other CFTR modulators or therapies to evaluate synergistic effects for potential clinical applications.